KOREA LIFE SCIENCE WEEK

2025 Exhibitors Search

Search Reset
All Number
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

※ Click on the participating company name below to see more information by company.

  • Korea Brain Research Institute PARTNERING (T1)Repurposing Ibrutinib and Abemaciclib: Therapeutic Effects in Alzheimer’s Disease, (T2)Composition for Preventing and Treating Diseases Related to TDP-43 Korea, South H60
  • Korea Corporation Security KOREA LIFE SCIENCE GxP Solution, Computer Software Assurance, CSV Service Korea, South F51
  • Korea Drug Research Association KOREA LIFE SCIENCE Promotion of Demand-Driven Strategic Programs for an R&D-Centered Pharmaceutical Industry Korea, South E36
  • Korea Institute of Science and Technology PARTNERING Compositions for preventing or treating allergic disease comprising extracts of Asiasarum sieboldi, Platycodon grandiflorum and Cinnamomum cassia Korea, South H60
  • Korea national institute for bioethics policy NextRegenX Support program for public IRB specializing in regenerative medicine Korea, South C22
  • Korea Safety Equipment Association KOREA LIFE SCIENCE Bio-Health Occupational Safety Pavilion Korea, South G35
  • KORINSTECH KOREA LAB Autumn Gel Hardness Tester, Tablet Hardness Tester, Leak Tester, Micro Leak Tester Korea, South F12
  • Liberi-CCubeLab Inc. PARTNERING Liberi-CCubeLab is a global licensing & BD consulting firm specializing in the pharmaceutical and bio sectors. It is a joint venture between Liberi Group (global leading L&BD consulting firm in Europe) and C Cube Lab (leading biotech business consulting firm in Korea). This JV was launched by combining the capabilities of both companies to enhance and maximize the performance of global licensing and co-development advisory services for Korean bio companies. We provide professional consulting services for implementing global licensing-out, co-development, and investment attraction, by combining Liberi Group’s extensive global L&BD success experience with C Cube Lab’s domestic and international expertise in business strategy, market research, and business deals in the bio sector. Korea, South C60
  • Liflex Science Inc PARTNERING We aim to develop an oligonucleotide cartilage regeneration injection targeting miR-204, a key factor in the development of degenerative arthritis. Specifically, we have identified a target pathogenic factor that not only prevents disease progression but also induces cartilage regeneration. Furthermore, we have identified a substance that effectively inhibits this pathogenic factor and are conducting efficacy and toxicity testing. Korea, South A60
  • Live Cell Instrument Co., Ltd. NextRegenX Cell Culture Support Systems Korea, South B25
처음페이지 11121314151617181920 마지막페이지